A Case of Response to Combination Treatment with TSA-DC-CTL Immunotherapy and Osimertinib in EGFR Mutated Advanced Lung Adenocarcinoma

Scientists demonstrated the safety and efficacy of TSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions.